alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['G696A'],"[{'ncitCode': 'C115977', 'drugName': 'Larotrectinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['30333516', '26546295', '29466156', '28578312']","[{'link': 'https://tptherapeutics.com/wp-content/uploads/AACR_2019_TRK_Final_S.pdf', 'abstract': 'Drilon et al. Abstract# 4000, AACR 2019.'}]","Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. NTRK3 G696A is listed in the FDA label for larotrectinib as a resistance mutation. One patient with an NTRK-fusion-positive tumor acquired NTRK3 G696A and NTRK1 G623R co-mutations upon progression on larotrectinib (PMID: 29466156). This mutation is a gatekeeper residue and has demonstrated in vitro resistance to larotrectinib (PMID: 30333516, 26546295, 28578312)(Abstract: Drilon et al. Abstract# 4000, AACR 2019. https://tptherapeutics.com/wp-content/uploads/AACR_2019_TRK_Final_S.pdf)"
